Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28175829 | 0.88 | PDE2A (0.43) | FFAR4FFAR1POLBPDE2ASCN9A | |
| SCHEMBL28783326 | 0.84 | HMGCR (0.45) | POLBEPHX2HDAC3HDAC1HDAC2 | |
| SCHEMBL29786514 | 0.82 | ABL1 (0.46) | FFAR4FFAR1ABL1SCN9AEPHX2 | |
| SCHEMBL17480164 | 0.82 | ABL1 (0.46) | FFAR4FFAR1ABL1SCN9AEPHX2 | |
| SCHEMBL27837804 | 0.81 | HSP90AB1 (0.60) | POLBHDAC3HDAC1HDAC2 | |
| SCHEMBL17478821 | 0.81 | ABL1 (0.45) | FFAR4FFAR1ABL1SCN9AEPHX2 | |
| SCHEMBL1697975 | 0.80 | IGF2BP2 (0.50) | FFAR4FFAR1ABL1EPHX2PIM1 | |
| SCHEMBL27719541 | 0.80 | THRB (0.45) | POLBEPHX2HDAC3HDAC1HDAC2 | |
| SCHEMBL30468358 | 0.79 | CHEK1 (0.47) | FFAR4FFAR1ABL1EPHX2BRAF | |
| SCHEMBL1795070 | 0.79 | ALDH1A1 (0.44) | FFAR4FFAR1ABL1SCN9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520423-A | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | FFAR4 3545/4885FFAR1 4353/4885ABL1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.